- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, NEJM 2022, n=2,539) Semaglutide Prescribing Information (FDA, 2025) Tirzepatide Prescribing Information (FDA, 2025) Self-Monitoring via Digital Health in Weight Loss Interventions: A Systematic Review Among Adults with Overweight or Obesity What Real Weight Tracker Users Say About Staying With It The Scale Matters Less When the Whole Week Makes Sense A weight loss tracker app only matters if it keeps someone going past week one
In the sections below, Ill break down every tier from per-milligram research costs today to projected post-approval retail pricing so you can make informed decisions for your research program
From $199/mo Voted Most Effective You did it
Exposure to GLP-1 RAs was consistently associated with significantly reduced odds of SUD cases
While the semaglutide CVOTs did not show an increased incidence of hospitalization for HF compared to placebo ( Several clinical mechanistic trials provided conflicting evidence while aiming to understand the GLP-1RA-induced heart rate-increase
In univariate analysis, adults who were prescribed an incretin-based drug had lower risk for all-cause mortality (HR = 0.18